U.S. Paper and Forestry Products Stock News

Douglas Emmett (DEI) is back in focus after its second quarter 2026 earnings update, which showed modestly higher revenue, a smaller net loss and refreshed guidance tied to leasing performance and debt refinancing. See our latest analysis for Douglas Emmett. Douglas Emmett’s latest earnings update has come after a mixed period for investors, with the share price up 5.6% year to date but the 1 year total shareholder return down 13.45%. The modest 1 day share price gain of 1.65% around the time...

Rocket Companies (RKT) drew investor attention after releasing second quarter 2026 results, reporting revenue of US$2.78b and net income of US$230 million, compared with a small loss a year earlier. See our latest analysis for Rocket Companies. Rocket Companies’ share price has reacted positively to the earnings release in the very short term, with a 1 day share price return of 3.78% and 7 day share price return of 6.36%. However, the year to date share price return is down 30.99%, while the...

Why Iovance Biotherapeutics Stock Is Back in Focus After Q2 Earnings Iovance Biotherapeutics (IOVA) is back on investors radar after reporting second quarter 2026 results. The company posted higher revenue, a smaller net loss and reaffirmed full year revenue guidance in the US$350 million to US$370 million range. See our latest analysis for Iovance Biotherapeutics. The latest Q2 report and reaffirmed revenue outlook have arrived after a strong run in Iovance Biotherapeutics share price, with...

A sudden mobile outage that left thousands of Verizon, AT&T and T-Mobile customers without reliable service has thrown a spotlight on how vulnerable everyday connectivity can feel. When networks falter, reputations and revenue are both at risk, which can quickly reshape how investors view telecom related stocks. This article walks through 3 stocks exposed to the news, all with potential downside to consider, so you can judge whether the risk is worth your capital. Verizon Communications...

BioNTech (NasdaqGS:BNTX) cut its 2026 revenue guidance to a range of €1,600 million to €1,900 million from €2,000 million to €2,300 million. The update followed second quarter results, which showed higher losses and lower sales. See our latest analysis for BioNTech. BioNTech's share price has moved to $93.67 after the guidance cut and wider earnings release, with a 7 day share price return of 3.41% and a year to date share price return that is down 3.12%. Over a longer window, momentum has...

NextNav’s 5G PNT Deal With Safran NextNav (NN) drew investor attention after announcing an agreement with Safran Electronics & Defense to integrate its terrestrial 5G positioning, navigation, and timing network with Safran’s timing and navigation receiver in Santa Clara County. The collaboration focuses on testing how 5G powered 3D PNT signals can complement GPS and other GNSS technologies for drones, autonomous systems, public safety, and critical infrastructure that rely on assured...

Madrigal Pharmaceuticals, Inc. reported second-quarter 2026 results showing a net loss of US$57.94 million, up from US$42.28 million a year earlier, and a six-month net loss of US$152.33 million versus US$115.52 million previously. This widening loss profile highlights the cost intensity of scaling its MASH-focused business at a time when investors are closely watching progress toward profitability. Next, we’ll examine how this larger quarterly net loss shapes Madrigal’s existing investment...

Capital Clean Energy Carriers Corp. recently reported second-quarter 2026 results showing higher sales year-on-year, continued vessel deliveries including the LNG carrier Alcaios I, and announced a new two‑year US$20.0 million share repurchase program under which it has already bought back 99,411 shares for US$2.14 million. Together with ongoing dividend payments and a reported contract backlog that could reach into the billions with options, these moves highlight management’s focus on...

Radian Group stock reacts to Q2 results and recent buybacks Radian Group (RDN) is back in focus after second quarter 2026 results highlighted strong revenue, resilient mortgage insurance trends, and the first full quarter contribution from specialty insurer Inigo, alongside ongoing share repurchases. See our latest analysis for Radian Group. Radian Group's latest report and buyback activity land against a mixed share price backdrop, with a 1 day share price return of 1.79% but a 7 day share...

Cactus, Inc. reported past second-quarter 2026 results with revenue of US$449.53 million and net income of US$49 million, alongside a 7% increase in its quarterly dividend to US$0.15 per Class A share and the appointment of industry veteran Joseph Elkhoury to its expanded Board. However, management’s expectation that third-quarter revenue will be slightly lower than the second quarter introduces a more cautious near-term outlook despite the strong recent performance and higher shareholder...

In early August 2026, Heritage Insurance Holdings, Inc. reported second-quarter 2026 results showing revenue of US$214.2 million and net income of US$61.71 million, alongside the completion of a buyback of 555,024 shares for US$12.53 million. The combination of higher earnings, improved underwriting metrics, and active share repurchases highlights management’s focus on profitability and capital efficiency in a catastrophe-exposed insurance portfolio. We’ll now examine how this stronger...

Why CorVel’s Latest Earnings Matter For Investors CorVel (CRVL) reported first quarter 2026 results on 5 August, with higher sales, net income, and earnings per share compared with the same period a year earlier, drawing fresh attention to the stock. The company also updated investors on recent share repurchases alongside the earnings release. This adds another factor for you to weigh when assessing CorVel’s valuation and longer term return potential. See our latest analysis for...

Atmus Filtration Technologies just saw its stock drop about 6% in a single session, yet the earnings story reads very differently. Q2 revenue reached about US$528m with adjusted earnings per share near US$0.82, and adjusted EBITDA margin sat just over 20%. For an industrial filtration business, that combination of scale and profitability is the real headline. The market is reacting to the shock of the price move, while the fundamentals point to a company that just reported one of its...

Why BKV stock is back in focus after the latest quarterly update BKV (BKV) moved back onto investor watchlists after reporting record adjusted earnings for the June quarter, with upstream production at the high end of guidance and fresh capital plans for power projects. See our latest analysis for BKV. The latest earnings and production updates have put BKV back in the spotlight, yet the share price tells a more cautious story. The 90 day share price return declined 13.69% and the year to...

O'Reilly Automotive, Inc. recently reported second-quarter 2026 results showing higher sales of US$4.89 billion and increased net income of US$715.06 million, raised its full-year 2026 revenue and earnings guidance, completed a large share repurchase program, and outlined a preference for smaller tuck-in acquisitions over large deals. The combination of stronger earnings, more optimistic full-year guidance, and disciplined capital allocation through buybacks and selective acquisitions...

Mach Natural Resources (MNR) stock is reacting to a busy set of August updates. The company reported second quarter 2026 earnings, refreshed production guidance, and confirmed a quarterly cash distribution of US$0.36 per common unit. See our latest analysis for Mach Natural Resources. At a share price of US$12.96, Mach Natural Resources has seen short term share price weakness, including a 1 day share price return that declined 2.70% and a 7 day share price return that declined 4.99%. The...

In early August 2026, Power Integrations reported second-quarter 2026 results showing higher sales of US$118.94 million and stronger profitability year on year, while also affirming a US$0.215 per-share dividend and issuing third-quarter revenue guidance of US$122 million to US$130 million. The company also announced that its PowiGaN gallium-nitride technology is now rated up to 2,200 V, a step that could expand its role in high-voltage applications such as data centers, electric vehicles,...

Evolv Technologies Holdings (EVLV) just landed a multi-year role as the official fan screening provider for Northwestern University’s new Ryan Field, placing its Evolv Express system at the center of a high-visibility stadium opening. See our latest analysis for Evolv Technologies Holdings. That new Ryan Field contract arrives during a mixed period for Evolv Technologies Holdings, with the share price at US$6.13 after a 10.85% 7 day share price return but a year to date share price return...

Solventum stock has quietly put up a 13.1% return over the past year, and the valuation checks now suggest the shares lean toward the cheaper side rather than looking stretched after that move. Over the past 12 months Solventum has returned 13.1%, which is enough to make the current pricing worth a closer look rather than assuming it is either a bargain or overheated. The planned separation of the Health Information Systems software business may support a sharper focus on MedTech returns...

Agilysys, Inc. reported past first-quarter 2026 results with revenue of US$87.68 million and net income of US$8.99 million, materially higher than a year earlier, and raised its fiscal 2027 revenue and subscription growth guidance. The combination of stronger profitability and higher full-year subscription growth targets points to increasing operating leverage in Agilysys’ hospitality software model. Next, we’ll explore how this stronger quarter and higher full-year revenue outlook may...

In August 2026, Pharvaris reported that its first in-depth qualitative study of patients with acquired C1 inhibitor deficiency (AAE-C1INH) was published in Frontiers in Immunology, detailing disease burden and validating patient-reported outcome tools for this ultra-rare condition with no approved therapies. The study’s insights directly informed endpoint selection for Pharvaris’s ongoing Phase 3 CREAATE trial of deucrictibant, potentially strengthening how future clinical benefits are...

In early August 2026, Monte Rosa Therapeutics, Inc. reported second-quarter results showing its net loss widened to US$43.4 million, with basic and diluted loss per share from continuing operations of US$0.43, and a first-half net loss of US$87.9 million versus net income a year earlier. The sharp shift from profit to loss over six months highlights growing cost intensity and brings funding requirements and potential dilution risk into sharper focus for investors. Against this backdrop,...

Everforth stock has rebounded sharply in the past month, yet multiple valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) model both still point to the shares trading below what the fundamentals imply. Everforth is up 83.7% over the past month, which sharply changes the recent share price picture but still leaves longer term returns weak. The key support for valuation is the market's expectation that Everforth can turn its business performance into stronger...

Why NewMarket earnings and buybacks matter for shareholders now NewMarket (NEU) just released second quarter 2026 results alongside a buyback progress update, providing fresh data on profitability, cash deployment, and how management is handling capital returns. The company reported second quarter sales of US$747.09 million and net income of US$133.75 million, with basic earnings per share from continuing operations of US$14.54. These figures sit alongside a completed multi year repurchase...